Angelini Industries: in 2024 net income up 30% to € 156 million. Group revenues (+3%) and EBITDA (+17%) also on the rise

Revenues grow in all business areas: +3.6% in pharma, +7.1% in industrial technology and robotics 

This is the Group's first financial statements prepared based on IFRS

Rome, June 25, 2025 - The 2024 financial statements of Angelini Industries, the Italian industrial group, with 5,600 employees in 21 countries, active in the healthcare, industrial technology and consumer goods sectors, closed with significantly increased numbers.

The Group includes Angelini Pharma, which, together with the corporate venture capital fund Angelini Ventures, operates in the healthcare sector; Angelini Technologies - Fameccanica, which develops innovative industrial technology and robotics solutions and just this year celebrates its 50th anniversary; Fater, a 50/50 joint venture with P&G, a leader in the absorbent and home care products sector; and Angelini Wines & Estates, the Group's wine company.

Sergio Marullo di Condojanni, CEO of Angelini Industries, said, “We are extremely pleased with our 2024 results, which once again reflect the Group’s ability to grow, especially in our two most strategic business areas for the future: healthcare and industrial technology. Compared to the previous year, we recorded a 3% revenue increase on a like-for-like basis and a double-digit EBITDA growth of 17%. This reflects our commitment in recent years to improving profitability through a continuous focus on efficiency. This isn’t just margin growth from cost-cutting. It’s a more structurally profitable position that we’re building through several ongoing initiatives: governance reform, process improvements, more effective operations, and a strong focus on our supply chain.”

The first "IFRS compliant" financial statements

Angelini Industries' financial statements for the year ending December 31, 2024 are the first to be prepared in accordance with International Financial Reporting Standards (IFRS), following the conclusion of the transition process aimed at aligning the Group's performance with international standards. Under the new accounting policies, the figures for Fater are no longer consolidated in proportion to the share held, but according to the equity method.

Key Findings 2024

The first key indicator to show a sharp increase in 2024 is the Group's net income, which, compared to the previous year, grew by 30% to 156 million euros, compared to pretax income of 177 million euros (+27% vs. 2023). Revenues grew by 3% to €1.6 billion[1] . EBITDA also rose (+17% vs. 2023) to €238 million, while EBIT of €107 million marks a year-on-year increase of +43%. The Group's net financial position also improved significantly, reaching € 933 million, an increase of +42% over 2023. Of this, € 432 million refers to financial receivables from the parent company Angelini Finanziaria related to cash pooling activities.

* Data prepared in accordance with International Financial Reporting Standards (IFRS)

Group and operating companies’ revenues

Angelini Industries’ revenue breakdown shows that 77% comes from the healthcare segment, 14% from industrial technology and robotics, and the remaining 9% from consumer goods. Geographically, 37% of revenues come from the Italian market, 49% from Europe, and 14% from the rest of the world.

Specifically, in the healthcare segment, in 2024 Angelini Pharma reported revenues of € 1,207.3 million (up +3.6% year-on-year), more than half of which, 50.6%, in international markets. EBITDA also rose to € 302.4 million (+14% vs 2023), with an EBITDA margin of 25% (22.8% in 2023). Also on the rise is the company's commitment to R&D, which amounted to € 62 million in 2024.

In the field of industrial technology, Angelini Technologies - Fameccanica, achieved revenues of € 244.7 million in 2024 (+7.1% vs 2023), 92% of which were in international markets. Particularly significant was the increase in orders (+49% vs. 2023) for a total of € 422 million in 2024. Positive sign also for EBITDA, amounting to € 27.5 million (+30% vs. 2023) and EBITDA margin standing at 11.2% (9.3% in 2023).

Investments in biotech and digital health

Investments by Angelini Ventures, the international venture capital firm of Angelini Industries with a fund of up to €300 million, which invests in start-ups and innovative companies in the fields of biotechnology and digital health, are also growing. Specifically, as of December 31, 2024, the capital disbursed by the corporate venture capital fund was approximately €80 million, with a total of 17 investments made.

[1] Under the previously applied accounting standards, they would have been more than 2.2 billion euros

***

Angelini Industries is a multinational industrial group founded in Ancona in 1919 by Francesco Angelini. Today it represents a solid and articulated industrial reality that employs about 5,600 people and operates in 21 countries worldwide with revenues of 1.6 billion euros. Angelini Industries operates in the Health, Industrial Technology and consumer goods sectors. Led by the Angelini family for more than 100 years, the industrial group is characterized by an investment strategy focused on growth, a governance model that combines the long-term vision of family businesses with the practices of publicly traded companies, an in-depth knowledge of markets and business sectors, and a commitment to promoting sustainable growth for people, communities, ecosystems and the planet.

***

Media contacts

Angelini Industries

Alessandra Favilli - Group Chief Communication Officer

alessandra.favilli@angeliniholding.compress@angeliniindustries.com -

SEC Newgate Italy

Daniele Pinosa -daniele.pinosa@secnewgate.it - tel. +39 3357233872

Fausta Tagliarini -fausta.tagliarini@secnewgate.it - tel. +39 3476474513

Daniele Murgia -daniele.murgia@secnewgate.it - tel. +39 3384330031

Giulia Cominotti - giulia.cominotti@secnewgate.it  - tel. +39 3391499949